Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers.

about

Pharmacokinetics of selective β1-adrenergic blocking agents: prescribing implications.

P2860

Q38226352-16AACB58-F57F-4F2C-B4E1-710C36EA08AB

P2860

Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers.

Item

http://www.wikidata.org/entity/Q38193200

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers.

@en

type

Item

label

Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers.

@en

prefLabel

Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers.

@en

P1476

Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers.

@en

P2093

Carlos Alberto Taira

http://www.w3.org/2001/XMLSchema#string

Christian Höcht

http://www.w3.org/2001/XMLSchema#string

Facundo Martín Bertera

http://www.w3.org/2001/XMLSchema#string

Julieta Sofía Del Mauro

http://www.w3.org/2001/XMLSchema#string

P2860

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate

PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol.

Heart rate as a target of treatment of chronic heart failure

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency

Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia.

Pharmacokinetic-pharmacodynamic modeling: why?

Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.

Stereoselective chromatography of cardiovascular drugs: an update.

P304

525-541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2014.885951

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24593316

http://www.w3.org/2001/XMLSchema#string

Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers.

about

P2860

P2860

Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698